Research programme: retinoic acid receptor gamma agonists - Lycera

Drug Profile

Research programme: retinoic acid receptor gamma agonists - Lycera

Alternative Names: ACT therapy - Lycera; Adoptive T cell transfer therapy - Lycera; RORgamma agonist - Lycera; RORγ agonists - Lycera

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lycera
  • Class Antineoplastics; Cell therapies; Small molecules
  • Mechanism of Action Cell replacements; Immunostimulants; Nuclear receptor subfamily 1 group F member 3 agonists; Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Colorectal cancer

Most Recent Events

  • 19 Apr 2016 Interim pharmacodynamics data from a Preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Jan 2016 Retinoic acid receptor gamma agonists licensed to Celgene
  • 09 Jun 2015 Lycera and Celgene agree to co-develop Retinoic acid receptor gamma agonists worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top